192 related articles for article (PubMed ID: 37089387)
61.
Wangsiricharoen S; Zhong M; Ranganathan S; Matoso A; Argani P
Int J Surg Pathol; 2021 Oct; 29(7):808-814. PubMed ID: 33729862
[TBL] [Abstract][Full Text] [Related]
62. Xp11.2 translocation renal cell carcinoma with NONO-TFE3 gene fusion: morphology, prognosis, and potential pitfall in detecting TFE3 gene rearrangement.
Xia QY; Wang Z; Chen N; Gan HL; Teng XD; Shi SS; Wang X; Wei X; Ye SB; Li R; Ma HH; Lu ZF; Zhou XJ; Rao Q
Mod Pathol; 2017 Mar; 30(3):416-426. PubMed ID: 27934879
[TBL] [Abstract][Full Text] [Related]
63. Papillary Renal Cell Carcinoma in Transplanted Kidney and Xp11.2 Translocation/Transcription Factor E3-Rearranged Renal Cell Carcinoma in the Native Kidney: A Case Report.
Kim MH; Kim KA; Kim JW; Lee SY; Choi JW
J Korean Soc Radiol; 2024 Mar; 85(2):437-444. PubMed ID: 38617860
[TBL] [Abstract][Full Text] [Related]
64.
Aldera AP; Ramburan A; John J
Urol Case Rep; 2022 May; 42():102041. PubMed ID: 35530544
[TBL] [Abstract][Full Text] [Related]
65. Minimally invasive cytologic evaluation leading to the diagnosis of TFE3-rearranged renal cell carcinoma: A case report.
Gama A; Sukhanova M; Choy B
Diagn Cytopathol; 2022 Dec; 50(12):E382-E385. PubMed ID: 35975764
[TBL] [Abstract][Full Text] [Related]
66. Renal cell carcinoma with t(6:11) (p21;q12). A case report highlighting distinctive immunohistologic features of this rare tumor.
Arneja SK; Gujar N
Int J Surg Case Rep; 2015; 7C():16-9. PubMed ID: 25562596
[TBL] [Abstract][Full Text] [Related]
67. NEAT1-TFE3 and KAT6A-TFE3 renal cell carcinomas, new members of MiT family translocation renal cell carcinoma.
Pei J; Cooper H; Flieder DB; Talarchek JN; Al-Saleem T; Uzzo RG; Dulaimi E; Patchefsky AS; Testa JR; Wei S
Mod Pathol; 2019 May; 32(5):710-716. PubMed ID: 30622287
[TBL] [Abstract][Full Text] [Related]
68. Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas.
Martignoni G; Pea M; Gobbo S; Brunelli M; Bonetti F; Segala D; Pan CC; Netto G; Doglioni C; Hes O; Argani P; Chilosi M
Mod Pathol; 2009 Aug; 22(8):1016-22. PubMed ID: 19396149
[TBL] [Abstract][Full Text] [Related]
69. Update on Selected High-grade Renal Cell Carcinomas of the Kidney: FH-deficient, ALK-rearranged, and Medullary Carcinomas.
Chen YB
Adv Anat Pathol; 2024 Mar; 31(2):118-125. PubMed ID: 38145398
[TBL] [Abstract][Full Text] [Related]
70. Histological and molecular characterization of TFEB-rearranged renal cell carcinomas.
Wyvekens N; Rechsteiner M; Fritz C; Wagner U; Tchinda J; Wenzel C; Kuithan F; Horn LC; Moch H
Virchows Arch; 2019 May; 474(5):625-631. PubMed ID: 30706129
[TBL] [Abstract][Full Text] [Related]
71. ALK-rearranged renal cell carcinoma with TPM3::ALK gene fusion and review of the literature.
Galea LA; Hildebrand MS; Witkowski T; Joy C; McEvoy CR; Hanegbi U; Aga A
Virchows Arch; 2023 Mar; 482(3):625-633. PubMed ID: 36370168
[TBL] [Abstract][Full Text] [Related]
72. The New WHO Category of "Molecularly Defined Renal Carcinomas": Clinical and Diagnostic Features and Management Implications.
Kanakaraj J; Chang J; Hampton LJ; Smith SC
Urol Oncol; 2024 Jul; 42(7):211-219. PubMed ID: 38519377
[TBL] [Abstract][Full Text] [Related]
73. Eosinophilic solid and cystic renal cell carcinoma and renal cell carcinomas with TFEB alterations: a comparative study.
Lobo J; Rechsteiner M; Helmchen BM; Rupp NJ; Weber A; Moch H
Histopathology; 2022 Jul; 81(1):32-43. PubMed ID: 35403742
[TBL] [Abstract][Full Text] [Related]
74. Sarcomatoid renal cell tumor harboring a novel BYSL::TFEB fusion with concurrent TFEB amplification.
Lin R; Flerova E; Wamsley CE; McCue PA; Lallas CD; Jiang W; Huang J; Wang ZX; Li L
Genes Chromosomes Cancer; 2023 Jun; 62(6):353-360. PubMed ID: 36704911
[TBL] [Abstract][Full Text] [Related]
75. MiTF/TFE Translocation Renal Cell Carcinomas: From Clinical Entities to Molecular Insights.
Simonaggio A; Ambrosetti D; Verkarre V; Auvray M; Oudard S; Vano YA
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886994
[TBL] [Abstract][Full Text] [Related]
76. Diagnosis of adults Xp11.2 translocation renal cell carcinoma by immunohistochemistry and FISH assays: clinicopathological data from ethnic Chinese population.
Qu Y; Gu C; Wang H; Chang K; Yang X; Zhou X; Dai B; Zhu Y; Shi G; Zhang H; Ye D
Sci Rep; 2016 Feb; 6():21677. PubMed ID: 26880493
[TBL] [Abstract][Full Text] [Related]
77. Targeted next-generation sequencing revealed distinct clinicopathologic and molecular features of VCL-ALK RCC: A unique case from an older patient without clinical evidence of sickle cell trait.
Wang XT; Fang R; Ye SB; Zhang RS; Li R; Wang X; Ji RH; Lu ZF; Ma HH; Zhou XJ; Xia QY; Rao Q
Pathol Res Pract; 2019 Nov; 215(11):152651. PubMed ID: 31563285
[TBL] [Abstract][Full Text] [Related]
78. Characteristics of Renal Cell Carcinoma Harboring
Woo CG; Yun SJ; Son SM; Lim YH; Lee OJ
Yonsei Med J; 2020 Mar; 61(3):262-266. PubMed ID: 32102128
[TBL] [Abstract][Full Text] [Related]
79. A Rare Partner of TFE3 in the Xp11 Translocation Renal Cell Carcinoma: Clinicopathological Analyses and Detection of MED15-TFE3 Fusion.
Ye H; Qin S; Li N; Lin M; Xu Y; Li X
Biomed Res Int; 2019; 2019():5974089. PubMed ID: 31828108
[TBL] [Abstract][Full Text] [Related]
80. TFEB rearranged renal cell carcinoma. A clinicopathologic and molecular study of 13 cases. Tumors harboring MALAT1-TFEB, ACTB-TFEB, and the novel NEAT1-TFEB translocations constantly express PDL1.
Caliò A; Harada S; Brunelli M; Pedron S; Segala D; Portillo SC; Magi-Galluzzi C; Netto GJ; Mackinnon AC; Martignoni G
Mod Pathol; 2021 Apr; 34(4):842-850. PubMed ID: 33208882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
